Coherus Oncology (CHRS) Income from Discontinued Operations (2024 - 2026)

Coherus Oncology has disclosed Income from Discontinued Operations across 3 years of filings, most recently posting $12.7 million for Q2 2026.

• In Q2 2026, Income from Discontinued Operations fell 96.29% year-over-year to $12.7 million; the TTM figure through Jun 2026 stood at $29.0 million (down 92.07% YoY), while the FY2025 annual figure was $351.1 million, up 43.97% from the prior year.
• Income from Discontinued Operations came in at $12.7 million for Q2 2026 at Coherus Oncology, up from -$1.4 million in the prior quarter.
• In the past five years, Income from Discontinued Operations ranged from a high of $342.6 million in Q2 2025 to a low of -$9.2 million in Q1 2025.
• Average Income from Discontinued Operations over 3 years is $60.8 million, with a median of $10.9 million recorded in 2025.
• The largest YoY upside for Income from Discontinued Operations was 717.15% in 2025 against a maximum downside of 105.37% in 2025.
• Over 3 years, Income from Discontinued Operations stood at -$4.6 million in 2024, then jumped by 289.09% to $8.7 million in 2025, then surged by 46.09% to $12.7 million in 2026.
• Per Business Quant data, the three most recent Income from Discontinued Operations figures were $12.7 million in Q2 2026, -$1.4 million in Q1 2026, and $8.7 million in Q4 2025.